Ben Leach

Articles

Targeted PD-1 Therapy Offers Opportunity to Sequence Agents

August 30th 2012

Drugs that target the programmed death-1 pathway hold considerable promise for the treatment of patients with melanoma, particularly in integrating the agents into the sequence of therapy.

FDA Grants Priority Review to New Indication for Abiraterone Acetate

August 29th 2012

The FDA announced that Priority Review has been granted to abiraterone acetate for certain advanced prostate cancer cases based on positive data presented at the ASCO annual meeting.

Cabozantinib Shows Promise as Potent RET Inhibitor in MTC

August 22nd 2012

The ability of cabozantinib to inhibit the RET pathway contributed to the pivotal clinical trial findings demonstrating that the novel oral agent significantly improved PFS in patients with advanced MTC.

Researchers Determine Immune Parameters that Lead to Better Survival in Patients who Receive Sipuleucel-T

August 17th 2012

Researchers have determined that patients who received sipuleucel-T (Provenge, Dendreon) developed immune parameters that correlate to improved overall survival, giving researchers a better understanding of how the immunotherapy works at a cellular level to improve survival.

Exploring Ways to Broaden the Reach of Molecular Tumor Testing

August 17th 2012

The development of targeted therapies for a variety of tumor types has highlighted a greater need for widespread molecular testing to determine which patients have the mutations that these therapies target.

Myriad Genetics Maintains BRCA1 and BRCA2 Patents, Appellate Court Rules

August 16th 2012

On August 16, the US Federal Circuit Court of Appeals ruled 2-1 to uphold its original decision that Myriad Genetics has the right to hold the patent to the BRCA1 and BRCA2 genes.

Combination of Aflibercept and Topotecan Shows Activity in Patients With Small Cell Lung Cancer

August 10th 2012

Aflibercept combined with topotecan achieved slightly higher rates of PFS and disease control in patients with platinum-refractory, extensive-stage small cell lung cancer, compared with topotecan alone.

FDA Approves Marqibo for Rare Form of Leukemia

August 9th 2012

The FDA approved Marqibo to treat patients with Philadelphia chromosome-negative adult acute lymphoblastic leukemia following at least two relapses or failed treatment.

Combination of Anastrozole and Fulvestrant Improves Survival in Metastatic Breast Cancer

August 7th 2012

Researchers found that when anastrozole and fulvestrant are given in combination that patients with metastatic breast cancer experienced longer periods of PFS and OS.

FDA Approves Aflibercept for Metastastic Colorectal Cancer

August 3rd 2012

The FDA announced that aflibercept has been approved to treat metastatic colorectal cancer when given in combination with the FOLFIRI chemotherapy regimen.

Abiraterone Acetate Significantly Improves PFS in Metastatic Prostate Cancer

August 3rd 2012

An interim analysis of the COU-AA-302 trial investigating the use of abiraterone acetate (Zytiga) in chemotherapy-naïve patients with mCRPC showed a trend toward improvement in PFS and OS.

TS Expression Explored in ALK-positive NSCLC

August 1st 2012

Expression levels of thymidylate synthase may help point the way to new treatment options for patients with ALK-positive NSCLC, including combination therapy.

Maintenance Erlotinib Fails to Improve Survival in Ovarian Cancer

July 31st 2012

Erlotinib given as a maintenance therapy did not improve PFS or OS in patients with epithelial ovarian cancer who had received first-line platinum-based chemotherapy.

Study Supports Feasibility of Routine Molecular Screening of NSCLC in Community Setting

July 25th 2012

New study reveals that widespread molecular screening of non–small cell lung cancer is feasible and can be performed outside of large academic medical centers.

Sipuleucel-T Studies Support Earlier Use, Reveal Potential Biomarker

July 25th 2012

Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.

Tivozanib Improves PFS Versus Sorafenib in Patients With Renal Cell Carcinoma

July 24th 2012

Tivozanib increased progression-free survival and objective response rate in patients with renal cell carcinoma compared with sorafenib.

FDA Approves Carfilzomib for Relapsed Multiple Myeloma

July 23rd 2012

The FDA approved carfilzomib for patients with multiple myeloma who have received at least two prior lines of therapy.

FDA Approves Everolimus for Advanced Breast Cancer

July 23rd 2012

The FDA has approved everolimus for treating patients with hormone receptor-positive, HER2 negative breast cancer, when given in combination with the aromatase inhibitor exemestane.

Multidisciplinary Approaches Are Needed in Ovarian Cancer

July 23rd 2012

While ovarian cancer survival rates have improved slightly since the 1970s, the overall five-year survival for patients diagnosed with the tumor type lags behind the average rate of all cancers.

FDA Approves Cetuximab Plus FOLFIRI for Metastatic Colorectal Cancer

July 10th 2012

The FDA has approved cetuximab in combination with the FOLFIRI regimen as a first-line treatment for patients with mCRC who express EGFR and wild-type KRAS mutations.

NEXT PAGE
PREVIOUS PAGE